Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease

References

• Browning JD, Szczepaniak SL, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387–1395 (2004).
   PubMed Web of Science ®Google Scholar
• Dunn W, Xu R, Wingard DL et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am. J. Gastroenterol. 103, 2263–2271 (2008).
   PubMed Web of Science ®Google Scholar
• Bambha K, Belt P, Abraham M et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology 55(3), 769–780 (2012).
   PubMed Web of Science ®Google Scholar
• Farrell GC, Wong VW, Chitturi S. NAFLD in Asia – as common and important as in the West. Nat. Rev. Gastroenterol. Hepatol. 10(5), 307–318 (2013).
   PubMed Web of Science ®Google Scholar
• Sanyal A, Poklepovic A, Moyneur E et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr. Med. Res. Opin. 26, 2183–2191 (2010).
   PubMed Web of Science ®Google Scholar
• Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28, 27–38 (2008).
   PubMed Web of Science ®Google Scholar
• Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of fatty liver. Endocr. Rev. 29(7), 939–960 (2008).
   PubMed Web of Science ®Google Scholar
• Patton HM, Yates K, Unalp-Arida A et al. Association between metabolic syndrome and liver histology among children with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 105, 2093–2102 (2010).
   PubMed Web of Science ®Google Scholar
• Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35, 373–379 (2002).
   PubMed Web of Science ®Google Scholar
• Allender S, Rayner M. The burden of overweight and obesity-related ill health in the UK. Obes. Rev. 8(5), 467–473 (2007).
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Inflammation and metabolic disorders. Nature 444(7121), 860–867 (2006).
   PubMed Web of Science ®Google Scholar
• de Onis M, Blössner M, Borghi E. Global prevalence and trends of overweight and obesity among preschool children. Am. J. Clin. Nutr. 92(5), 1257–1264 (2010).
   PubMed Web of Science ®Google Scholar
• Bellentani S, Scaglioni F, Marino M et al. Epidemiology of non-alcoholic fatty liver disease. Dig. Dis. 28(1), 155–161 (2010).
   PubMed Web of Science ®Google Scholar
• Charlton MR, Burns JM, Pedersen RA et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141(4), 1249–1253 (2011).
   PubMed Web of Science ®Google Scholar
• Tiniakos DG. Liver biopsy in alcoholic and non-alcoholic steatohepatitis patients. Gastroenterol. Clin. Biol. 33(10–11), 930–939 (2009).
   Google Scholar
• Fukumoto M, Masuda K, Ogawa Y et al. In vivo imaging of hepatic fatty acid metabolism in patients with nonalcoholic steatohepatitis using semiquantative (123)I-BMIPP liver scan. Hepatol. Res. 33(2), 105 (2005).
   Google Scholar
• Wanless IR, Bargman JM, Oreopoulos DG, Vas SI. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity. Mod. Pathol. 2, 69–74 (1989).
   PubMed Web of Science ®Google Scholar
• Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin. Liver Dis. 24(1), 99–106 (2004).
   PubMed Web of Science ®Google Scholar
• Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin. Diagn. Pathol. 15(4), 246–258 (1998).
   PubMed Web of Science ®Google Scholar
• Brunt EM, Janney CG, Di Bisceglie AM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94(9), 2467–2474 (1999).
   PubMed Web of Science ®Google Scholar
• Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51(5), 1820–1832 (2010).
   PubMed Web of Science ®Google Scholar
• Day CP, James OF. Steatohepatitis: a tale of two ‘hits’. Gastroenterology 114, 842–845 (1998).
   PubMed Web of Science ®Google Scholar
• Lonardo A, Caldwell SH, Loria P. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert. Rev. Endocrinol. Metab. 5(3), 403–423 (2010).
   Google Scholar
• Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52(5), 1836–1846 (2010).
   PubMed Web of Science ®Google Scholar
• Erridge C, Samani NJ. Saturated fatty acids do not directly stimulate Toll-like receptor signaling. Arterioscler. Thromb. Vasc. Biol. 29, 1944–1949 (2009).
   PubMed Web of Science ®Google Scholar
• Monetti M, Levin MC, Watt MJ et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 6, 69–78 (2007).
   PubMed Web of Science ®Google Scholar
• Haemmerle G, Lass A, Zimmermann R et al. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 312, 734–737 (2006).
   PubMed Web of Science ®Google Scholar
• Stefan N, Häring HU. The metabolically benign and malignant fatty liver. Diabetes 60, 2011–2017 (2011).
   PubMed Web of Science ®Google Scholar
• Lehmann R, Franken H, Dammeier S et al. Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver. Diabetes Care 36, 2331–2338 (2013).
   Google Scholar
• Finelli C, Tarantino G. Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease? World J. Gastroenterol. 18(46), 6790–6800 (2012).
   PubMed Web of Science ®Google Scholar
• Charlton M, Krishnan A, Viker K et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am. J. Physiol. Gastrointest. Liver Physiol. 301(5), 825–834 (2011).
   PubMed Web of Science ®Google Scholar
• Sabio G, Das M, Mora A et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 322(5907), 1539–1543 (2008).
   PubMed Web of Science ®Google Scholar
• Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am. J. Physiol. Gastrointest. Liver Physiol. 295(5), G987–G995 (2008).
   PubMed Web of Science ®Google Scholar
• Ricchi M, Odoardi MR, Carulli L et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J. Gastroenterol. Hepatol. 24(5), 830–840 (2009).
   PubMed Web of Science ®Google Scholar
• Vos MB, Kimmons JE, Gillespie C et al. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J. Med. 10(7), 160 (2008).
   PubMedGoogle Scholar
• Kohli R, Kirby M, Xanthakos SA et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52(3), 934–944 (2010).
   PubMed Web of Science ®Google Scholar
• Selva DM, Hogeveen KN, Innis SM, Hammond GL. Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J. Clin. Invest. 117(12), 3979–3987 (2007).
   PubMed Web of Science ®Google Scholar
• Wallace IR, McKinley MC, Bell PM, Hunter SJ. Sex hormone-binding globulin and risk of Type 2 diabetes. Clin. Endocrinol. (Oxf.) 78(3), 321–329 (2013).
   PubMed Web of Science ®Google Scholar
• Ouyang X, Cirillo P, Sautin Y et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J. Hepatol. 48(6), 993–999 (2008).
   PubMed Web of Science ®Google Scholar
• Lustig RH. Fructose: it’s ‘alcohol without the buzz’. Adv. Nutr. 4(2), 226–235 (2013).
   PubMed Web of Science ®Google Scholar
• Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 50(4), 1094–1104 (2009).
   PubMed Web of Science ®Google Scholar
• Amar J, Burcelin R, Ruidavets JB et al. Energy intake is associated with endotoxemia in apparently healthy men. Am. J. Clin. Nutr. 87(5), 1219–1223 (2008).
   PubMed Web of Science ®Google Scholar
• Matsuzawa N, Takamura T, Kurita S et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46(5), 1392–1403 (2007).
   PubMed Web of Science ®Google Scholar
• Van Rooyen DM, Larter CZ, Haigh WG et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 141(4), 1393–1403.e1395 (2011).
   PubMed Web of Science ®Google Scholar
• Wouters K, Van Gorp PJ, Bieghs V et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48(2), 474–486 (2008).
   PubMed Web of Science ®Google Scholar
• Ferré N, Martínez-Clemente M, López-Parra M et al. Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. Am. J. Physiol. Gastrointest. Liver Physiol. 296(3), G553–G562 (2009).
   PubMed Web of Science ®Google Scholar
• Subramanian S, Goodspeed L, Wang S et al. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J. Lipid Res. 52(9), 1626–1635 (2011).
   PubMed Web of Science ®Google Scholar
• Lee JH, Wada T, Febbraio M et al. A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis. Gastroenterology 139(2), 653–663 (2010).
   PubMed Web of Science ®Google Scholar
• Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J. Hepatol. 56(1), 255–266 (2012).
   PubMed Web of Science ®Google Scholar
• Haus JM, Solomon TP, Marchetti CM, Edmison JM, González F, Kirwan JP. Free fatty acid-induced hepatic insulin resistance is attenuated following lifestyle intervention in obese individuals with impaired glucose tolerance. J. Clin. Endocrinol. Metab. 95(1), 323–327 (2010).
   Google Scholar
• Galli SJ, Borregaard N, Wynn TA. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat. Immunol. 12(11), 1035–1044 (2011).
   PubMed Web of Science ®Google Scholar
• Weisberg SP, Mccann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112(12), 1796–1808 (2003).
   PubMed Web of Science ®Google Scholar
• Kosteli A, Sugaru E, Haemmerle G et al. Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J. Clin. Invest. 120(10), 3466–3479 (2010).
   PubMed Web of Science ®Google Scholar
• Kanda H, Tateya S, Tamori Y et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 116(6), 1494–1505 (2006).
   PubMed Web of Science ®Google Scholar
• Weisberg SP, Hunter D, Huber R et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 116(1), 115–124 (2006).
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Delproposto JB, Westcott DJ, Saltiel AR. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 57(12), 3239–3246 (2008).
   PubMed Web of Science ®Google Scholar
• Wentworth JM, Naselli G, Brown WA et al. Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes 59(7), 1648–1656 (2010).
   PubMed Web of Science ®Google Scholar
• Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat. Rev. Immunol. 11(11), 738–749 (2011).
   PubMed Web of Science ®Google Scholar
• Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 8(4), 301–309 (2008).
   PubMed Web of Science ®Google Scholar
• Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J. Clin. Invest. 121(6), 2094–2101 (2011).
   PubMed Web of Science ®Google Scholar
• Hosogai N, Fukuhara A, Oshima K et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56(4), 901–911 (2007).
   PubMed Web of Science ®Google Scholar
• Suganami T, Tanimoto-Koyama K, Nishida J et al. Role of the Toll-like receptor 4/NF-κB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler. Thromb. Vasc. Biol. 27(1), 84–91 (2007).
   PubMed Web of Science ®Google Scholar
• Schipper HS, Prakken B, Kalkhoven E, Boes M. Adipose tissue-resident immune cells: key players in immunometabolism. Trends Endocrinol. Metab. 23(8), 407–415 (2012).
   PubMed Web of Science ®Google Scholar
• Strissel KJ, Stancheva Z, Miyoshi H et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 56(12), 2910–2918 (2007).
   PubMed Web of Science ®Google Scholar
• Winer DA, Winer S, Shen L et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med. 17(5), 610–617 (2011).
   PubMed Web of Science ®Google Scholar
• Boehm T. Design principles of adaptive immune systems. Nat. Rev. Immunol. 11(5), 307–317 (2011).
   PubMed Web of Science ®Google Scholar
• Deiuliis J, Shah Z, Shah N et al. Visceral adipose inflammation in obesity is associated with critical alterations in tregulatory cell numbers. PLoS ONE 6(1), e16376 (2011).
   PubMed Web of Science ®Google Scholar
• Nishimura S, Manabe I, Nagasaki M et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 15(8), 914–920 (2009).
   PubMed Web of Science ®Google Scholar
• Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology 48(2), 670–678 (2008).
   PubMed Web of Science ®Google Scholar
• Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unraveling the mechanism. Lancet 375(9733), 2267–2277 (2010).
   PubMed Web of Science ®Google Scholar
• Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72, 219–246 (2010).
   PubMed Web of Science ®Google Scholar
• Saberi M, Woods N-B, De Luca C et al. Hematopoietic cell-specific deletion of Toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab. 10(5), 419–429 (2009).
   PubMed Web of Science ®Google Scholar
• Arkan MC, Hevener AL, Greten FR et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 11(2), 191–198 (2005).
   PubMed Web of Science ®Google Scholar
• Cai D, Yuan M, Frantz DF et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat. Med. 11(2), 183–190 (2005).
   PubMed Web of Science ®Google Scholar
• Kim JK, Kim YJ, Fillmore JJ et al. Prevention of fat-induced insulin resistance by salicylate. J. Clin. Invest. 108(3), 437–446 (2001).
   PubMed Web of Science ®Google Scholar
• Senn JJ, Klover PJ, Nowak IA et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J. Biol. Chem. 278(16), 13740–13746 (2003).
   PubMed Web of Science ®Google Scholar
• Roden M. Mechanisms of disease: hepatic steatosis in Type 2 diabetes–pathogenesis and clinical relevance. Nat. Clin. Pract. Endocrinol. Metab. 2(6), 335–348 (2006).
   PubMedGoogle Scholar
• Pagliassotti MJ, Wei Y, Wang D. Insulin protects liver cells from saturated fatty acid-induced apoptosis via inhibition of c-Jun NH2 terminal kinase activity. Endocrinology 148(7), 3338–3345 (2007).
   Google Scholar
• Schattenberg JM, Singh R, Wang Y et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 43(1), 163–172 (2006).
   PubMed Web of Science ®Google Scholar
• Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J. Hepatol. 39(6), 978–983 (2003).
   PubMed Web of Science ®Google Scholar
• Zou C, Ma J, Wang X et al. Lack of Fas antagonism by Met in human fatty liver disease. Nat. Med. 13(9), 1078–1085 (2007).
   PubMed Web of Science ®Google Scholar
• Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 8(1), 35–44 (2011).
   PubMed Web of Science ®Google Scholar
• Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48(1), 322–335 (2008).
   PubMed Web of Science ®Google Scholar
• Miura K, Kodama Y, Inokuchi S et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1β in mice. Gastroenterology 139(1), 323–334.e327 (2010).
   PubMed Web of Science ®Google Scholar
• Park EJ, Lee JH, Yu G-Y et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140(2), 197–208 (2010).
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Celedon MA, Lavine JE et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 136(5), 1585–1592 (2009).
   PubMed Web of Science ®Google Scholar
• Sazci A, Ergul E, Aygun C, Akpinar G, Senturk O, Hulagu S. Methylenetetrahydrofolate reductase gene polymorphisms in patients with nonalcoholic steatohepatitis (NASH). Cell Biochemi. Funct. 26(3), 291–296 (2008).
   Google Scholar
• Song J, da Costa KA, Fischer LM et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J. 19(10), 1266–1271 (2005).
   PubMed Web of Science ®Google Scholar
• Dong H, Wang J, Li C et al. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J. Hepatol. 46(5), 915–920 (2007).
   PubMed Web of Science ®Google Scholar
• Zhu X, Song J, Mar MH et al. Phosphatidylethanolamine N-methyltransferase (PEMT) knockout mice have hepatic steatosis and abnormal hepatic choline metabolite concentrations despite ingesting a recommended dietary intake of choline. Biochem. J. 370(Pt 3), 987–993 (2003).
   PubMed Web of Science ®Google Scholar
• Fan JG, Qiao L. Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat. Dis. Int. 8(3), 233–240 (2009).
   Google Scholar
• Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40(12), 1461–1465 (2008).
   PubMed Web of Science ®Google Scholar
• He S, Mcphaul C, Li JZ et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 285(9), 6706–6715 (2010).
   PubMed Web of Science ®Google Scholar
• Petersen KF, Dufour S, Hariri A et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 362(12), 1082–1089 (2010).
   PubMed Web of Science ®Google Scholar
• Kozlitina J, Boerwinkle E, Cohen JC, Hobbs HH. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 53(2), 467–474 (2011).
   PubMed Web of Science ®Google Scholar
• Hyysalo J, Stojkovic I, Kotronen A et al. Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 27(5), 951–956 (2012).
   PubMed Web of Science ®Google Scholar
• Hu ZW, Luo HB, Xu YM et al. Tumor necrosis factor–alpha gene promoter polymorphisms in Chinese patients with nonalcoholic fatty liver diseases. Acta Gastroenterol. Belg. 72(2), 215–221 (2009).
   PubMed Web of Science ®Google Scholar
• Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J. Hepatol. 46(6), 1104–1110 (2007).
   PubMed Web of Science ®Google Scholar
• Valenti L, Fracanzani AL, Dongiovanni P et al. Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122(2), 274–280 (2002).
   PubMed Web of Science ®Google Scholar
• Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 98(5), 960–967 (2003).
   PubMed Web of Science ®Google Scholar
• Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am. J. Med. Sci. 329(3), 111–116 (2005).
   PubMed Web of Science ®Google Scholar
• Wong VW-S, Chu WC-W, Wong GL-H et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 61(3), 409–415 (2012).
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Mcgreal N, Deutsch R, Finegold MJ, Lavine JE. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 115(5), e561–e565 (2005).
   PubMed Web of Science ®Google Scholar
• Kagansky N, Levy S, Keter D et al. Non-alcoholic fatty liver disease – a common and benign finding in octogenarian patients. Liver Internation. 24(6), 588–594 (2004).
   PubMed Web of Science ®Google Scholar
• Carr MC. The emergence of the metabolic syndrome with menopause. J. Clin. Endocrinol. Metab. 88(6), 2404–2411 (2003).
   PubMed Web of Science ®Google Scholar
• Ostberg JE, Thomas EL, Hamilton G, Attar MJH, Bell JD, Conway GS. Excess visceral and hepatic adipose tissue in turner syndrome determined by magnetic resonance imaging: estrogen deficiency associated with hepatic adipose content. J. Clin. Endocrinol. Metab. 90(5), 2631–2635 (2005).
   PubMed Web of Science ®Google Scholar
• Loria P CL, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat. Rev. Gastroenterol. Hepatol. 6(4), 236–247 (2009).
   Google Scholar
• Lonardo A, Loria P, Leonardi F, Ganazzi D, Carulli N. Growth hormone plasma levels in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 97(4), 1071–1072 (2002).
   Google Scholar
• Lonardo A, Carani C, Carulli N, Loria P. ‘Endocrine NAFLD’ a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J. Hepatol. 44(6), 1196–1207 (2006).
   PubMed Web of Science ®Google Scholar
• Ludwig J, Viggiano TR, Mcgill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55(7), 434–438 (1980).
   PubMed Web of Science ®Google Scholar
• Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J. Lipid Res. 49(5), 1068–1076 (2008).
   PubMed Web of Science ®Google Scholar
• Phung N, Pera N, Farrell G et al. Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. Int. J. Mol. Med. 24(2), 171–180 (2009).
   PubMed Web of Science ®Google Scholar
• Kodama Y, Kisseleva T, Iwaisako K et al. c-Jun N-terminal Kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology 137(4), 1467–1477.e1465 (2009).
   PubMed Web of Science ®Google Scholar
• Baumgardner JN, Shankar K, Hennings L, Badger TM, Ronis MJ. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am. J. Physiol. Gastrointest. Liver Physiol. 294(1), G27–G38 (2008).
   PubMed Web of Science ®Google Scholar
• Ogawa T, Fujii H, Yoshizato K, Kawada N. A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits. Am. J. Pathol. 177(1), 153–165 (2010).
   Google Scholar
• Arrese M. Burning hepatic fat: therapeutic potential for liver-specific thyromimetics in the treatment of nonalcoholic fatty liver disease. Hepatology 49(2), 348–351 (2009).
   PubMed Web of Science ®Google Scholar